Furthermore, meta-analyses of the randomized controlled trials showed that anti-IL-5 monoclonal antibodies, mepolizumab and benralizumab, could reduce annual moderate/severe exacerbation rates in eosinophilic COPD patients [86,87]. This evidence concerns the gene IL5 and chronic obstructive pulmonary disease.